Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry
基于生物正交点击化学的预靶向放射免疫治疗
基本信息
- 批准号:8993655
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-01 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:90YAdverse effectsAffinityAlder plantAnimalsAntibodiesAntibody AffinityAntibody SpecificityAntigensAwardBackground RadiationBehaviorBiodistributionBiologicalBloodChemistryClinicalColorectal CancerComplementComplicationContinuing EducationCoupledDataDepositionDevelopmentDisease modelDoseDrug KineticsElectronsEnvironmentEquilibriumExposure toFellowshipFosteringFoundationsFutureGPA33 geneGlycolsGoalsHandImageImmunoconjugatesIn VitroIndividualInjection of therapeutic agentInvestigationIsotopesKnowledgeLabelLaboratoriesLaboratory ResearchLeadLearningLengthLigationLinkMagnetic Resonance ImagingMalignant NeoplasmsMeasurementMeasuresMemorial Sloan-Kettering Cancer CenterMentorsMethodologyMolecularMonitorMusOrganPatientsPharmacologyPhasePositronPositron-Emission TomographyPre-Clinical ModelRadiationRadiation therapyRadioactivityRadioimmunotherapyRadioisotopesRadiolabeledRadiopharmaceuticalsReactionResearchResearch ProposalsResourcesScientistSeriesSiteSpecificityStructureSystemTargeted RadiotherapyTestingTherapeuticTherapeutic EffectTherapeutic UsesTherapeutic antibodiesTissuesTrainingTraining ProgramsTranslationsWorkXenograft procedureabstractingantibody conjugatebasecancer cellcancer imagingcancer therapycareercareer developmentchemical synthesiscytotoxicdesigndesign and constructionexperienceimmunoreactivityimprovedin vivoinsightmolecular imagingnovelnovel strategiesprogramsradiochemicalradioligandradiotracerresearch studyscaffoldskillssmall moleculesubcutaneoustheoriestooltumoruptakevector
项目摘要
Project Summary/Abstract
This proposal describes a training program to advance my academic career in the development of
strategies for the targeted radiotherapy of cancer. The purpose of this award is to encourage my independent
research program, and this period will be used to expand both my scientific knowledge and mentoring skills.
During the K99 award period, I will be mentored by Dr. Jason Lewis and co-mentored by Dr. David Scheinberg.
Dr. Lewis is an internationally recognized radiochemist and inorganic chemist with tremendous experience in
the synthesis, development, and clinical translation of radiopharmaceuticals for both the imaging and therapy
of cancer. Dr. Scheinberg, the chair of the Program in Molecular Pharmacology and Chemistry at Memorial
Sloan-Kettering Cancer Center, is an expert in the development and translation of targeted
radioimmunotherapeutics. Both Drs. Lewis and Scheinberg have mentored many scientists and clinical fellows,
several of whom have transitioned to successful academic careers. Memorial Sloan-Kettering Cancer Center
(MSKCC) will provide institutional support, including the resources to conduct laboratory research,
opportunities to foster career development and continuing education, and an open scientific environment to
foster the interaction required for me to achieve my goals.
The overall goal of this research proposal is for me to learn the fundamental theory and laboratory practice
of targeted radioimmunotherapy in the context of developing a novel strategy for the pretargeted
radioimmunotherapy of colorectal cancer. The proposal extends directly from my previous research
experience, as I have spent a significant portion of my postdoctoral fellowship investigating the application of
inverse electron-demand Diels-Alder `click' chemistry both to the synthesis of radiopharmaceuticals for positron
emission tomography (PET) and to the creation of antibody-based, pretargeted PET imaging strategies. This
research has established that Diels-Alder click chemistry is an extremely effective tool for the rapid, facile, and
modular construction of radiopharmaceuticals; further, this work has shown that this bioorthogonal click
chemistry can be employed as the foundation of a highly effective pretargeted PET imaging strategy.
The specific aim of this proposal during the 2-year K99 award period is the synthesis, chemical
characterization, and in vitro biological characterization of the molecular components of the pretargeted
radioimmunotherapy system, specifically the dienophile-modified, colorectal-cancer targeting huA33 antibody
and the tetrazine-bearing, 90Y- and 177Lu-labeled radioligands (Specific Aim 1). The specific aims for the 3-
year R00 award period extend from this aim and are to investigate the in vivo pharmacokinetics and
biodistribution of the pretargeted system and its individual molecular components (Specific Aim 2) and to
determine the in vivo efficacy of this pretargeted radioimmunotherapy strategy in preclinical models of
colorectal cancer (Specific Aim 3).
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Matthew Zeglis其他文献
Brian Matthew Zeglis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Matthew Zeglis', 18)}}的其他基金
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations
用于快速、稳定的硫醇基生物共轭的新型试剂
- 批准号:
10640245 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations
用于快速、稳定的硫醇基生物共轭的新型试剂
- 批准号:
9975105 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations
用于快速稳定的硫醇基生物共轭的新型试剂
- 批准号:
10408820 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations
用于快速、稳定的硫醇基生物共轭的新型试剂
- 批准号:
10208825 - 财政年份:2019
- 资助金额:
$ 24.9万 - 项目类别:
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry
基于生物正交点击化学的预靶向放射免疫治疗
- 批准号:
8700927 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
PET Imaging of Topoisomerase-II Expression in Breast Cancer
乳腺癌拓扑异构酶 II 表达的 PET 成像
- 批准号:
7803275 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
PET Imaging of Topoisomerase-II Expression in Breast Cancer
乳腺癌拓扑异构酶 II 表达的 PET 成像
- 批准号:
7970930 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
PET Imaging of Topoisomerase-II Expression in Breast Cancer
乳腺癌拓扑异构酶 II 表达的 PET 成像
- 批准号:
8126445 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




